Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 6,553 shares were traded during trading, an increase of 35% from the previous session's volume of 4,843 shares.The stock last traded at $8.72 and had previously closed at $8.20.
Analysts Set New Price Targets
A number of brokerages have weighed in on PHAR. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, December 17th. Oppenheimer cut their price objective on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Finally, Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They set a "buy" rating and a $14.00 target price for the company.
Check Out Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm's 50 day moving average price is $9.21 and its two-hundred day moving average price is $8.43.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
